Blanco O, Lugones Y, Fernández O, Faure R

Idioma: Español
Referencias bibliográficas: 60
Paginas: 53-59
Archivo PDF: 109.25 Kb.

RESUMEN

El surfactante pulmonar y las enfermedades respiratorias están estrechamente relacionados. La actividad adecuada del surfactante es esencial para la función óptima del pulmón en los seres humanos. Una disfunción secundaria del surfactante pulmonar puede contribuir al proceso de enfermedades pulmonares como el síndrome de insuficiencia respiratoria aguda, el asma, la fibrosis cística y las neumonías, entre otras. Los intentos de tratar estas enfermedades con surfactantes exógenos han sido parcialmente exitosos. Esta es una actualización referente a las preparaciones clínicas de surfactantes y sus funciones inmunomoduladoras, y lo que acontece en el mercado en relación con los ensayos clínicos que emplean estas preparaciones para mitigar enfermedades pulmonares. Los resultados de un análisis informacional muestran el potencial para extender tales preparaciones en el tratamiento de enfermedades respiratorias diferentes al síndrome de insuficiencia respiratoria aguda del neonato. La relevancia de las funciones inmunomoduladoras del surfactante pulmonar y la evaluación de su potencial formulación de conjunto con otros medicamentos, son un campo de investigación activo.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Veldhuizen R, Nag K, Orgeig S, Possmayer F. The role of lipids in pulmonary surfactant. Biochim Biophys Acta. 1998;1408(2-3):90-108.

2. Creuwels LA, van Golde LM, Haagsman HP. The pulmonary surfactant system: biochemical and clinical aspects. Lung. 1997;175(1):1-39.

3. Possmayer F. A proposed nomenclature for pulmonary surfactant-associated proteins. Am Rev Respir Dis. 1988;138(4):990-8.

4. Wright JR. Pulmonary surfactant: a front line of lung host defense. J Clin Invest. 2003;111(10):1453-5.

5. Engle WA. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics. 2008;121(2):419-32.

6. Baines KJ, Simpson JL, Gibson PG. Innate immune responses are increased in chronic obstructive pulmonary disease. PLoS One. 2011;6(3):e18426.

7. Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol. 2011;6:147-63.

8. Blanco O, Pérez-Gil J. Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat Respiratory Distress Syndrome: Role of the different components in an efficient pulmonary surfactant. Eur J Pharmacol. 2007;568(1-3):1-15.

9. Wright JR. Immunomodulatory functions of surfactant. Physiol Rev. 1997;77(4):931-62.

10. Tegtmeyer FK, Gortner L, Ludwig A, Brandt E. In vitro modulation of induced neutrophil activation by different surfactant preparations. Eur Respir J. 1996;9(4):752-7.

11. Hidi R, Vial D, Havet N, Berger A, Vargaftig BB, Touqui L. Inhibition by pulmonary surfactant Curosurf of secretory phospholipase A2 expression in guinea-pig alveolar macrophages. Biochem Pharmacol. 1997;54(9):1055-8.

12. Wu Y, Singer M, Thouron F, Alaoui-El-Azher M, Touqui L. Effect of surfactant on pulmonary expression of type IIA PLA(2) in an animal model of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2002;282(4):L743-50.

13. Walti H, Polla BS, Bachelet M. Modified natural porcine surfactant inhibits superoxide anions and proinflammatory mediators released by resting and stimulated human monocytes. Pediatr Res. 1997;41(1):114-9.

14. Gille C, Spring B, Bernhard W, Gebhard C, Basile D, Lauber K, et al. Differential effect of surfactant and its saturated phosphatidylcholines on human blood macrophages. J Lipid Res. 2007;48(2):307-17.

15. Erpenbeck VJ, Fischer I, Wiese K, Schaumann F, Schmiedl A, Nassenstein C, et al. Therapeutic surfactants modulate the viability of eosinophils and induce inflammatory mediator release. Int Arch Allergy Immunol. 2009;149(4):333-42.

16. Geiger R, Treml B, Pinna A, Barnickel L, Prossliner H, Reinstadler H, et al. Tolerability of inhaled N-chlorotaurine in the pig model. BMC Pulm Med. 2009;9:33.

17. Abate W, Alghaithy AA, Parton J, Jones KP, Jackson SK. Surfactant lipids regulate LPS-induced interleukin-8 production in A549 lung epithelial cells by inhibiting translocation of TLR4 into lipid raft domains. J Lipid Res. 2010;51(2):334-44.

18. Suwabe A, Otake K, Yakuwa N, Suzuki H, Ito M, Tomoike H, et al. Artificial surfactant (Surfactant TA) modulates adherence and superoxide production of neutrophils. Am J Respir Crit Care Med. 1998;158(6):1890-9.

19. Geertsma MF, Broos HR, van den Barselaar MT, Nibbering PH, van Furth R. Lung surfactant suppresses oxygen-dependent bactericidal functions of human blood monocytes by inhibiting the assembly of the NADPH oxidase. J Immunol. 1993;150(6):2391-400.

20. Antal JM, Divis LT, Erzurum SC, Wiedemann HP, Thomassen MJ. Surfactant suppresses NF-kappa B activation in human monocytic cells. Am J Respir Cell Mol Biol. 1996;14(4):374-9.

21. Bartmann P, Gortner L, Pohlandt F, Jaeger H. In vitro lymphocyte functions in the presence of bovine surfactant and its phospholipid fractions. J Perinat Med. 1992;20(3):189-96.

22. Blanco O, Beltran A, Gonzalez D, Sánchez J, Fernández O, Faure R, et al. Some anti-inflammatory properties of a natural pulmonary surfactant: Surfacen. Appl Cardiopulmonary Pathophysiol. 2000;9:201-3.

23. Blanco O, Riverón Y, de Armas E, Sánchez J, Faure R, Fernández O. SURFACEN® inhibits the growth of bacteria causing respiratory infections. Biotecnol Apl. 2005; 22:282-4.

24. Zhu Y, Miller TL, Chidekel A, Shaffer TH. KL4-surfactant (Lucinactant) protects human airway epithelium from hyperoxia. Pediatr Res. 2008;64(2):154-8.

25. Sanchez-Mendiola M, Martinez-Natera OC, Herrera-Maldonado N, Ortega-Arroyo J. Treatment of hyaline membrane disease in the preterm newborn with exogenous lung surfactant: a controlled study. Gac Med Mex. 2005;141(4):267-71.

26. Moreno Vázquez O, Lee López M, Domínguez Dieppa F, Pascual López MA, Alonso Abad A, Jiménez Rivero G, et al. Estudio de la eficacia del Surfacen en el distress respiratorio del recién nacido. Rev Cubana Pediatr. 1999;71:60-71.

27. Taeusch HW, Lu KW, Ramierez-Schrempp D. Improving pulmonary surfactants. Acta Pharmacol Sin. 2002;23(11 Suppl):S11-5.

28. Speer CP, Gefeller O, Groneck P, Laufkotter E, Roll C, Hanssler L, et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 1995;72(1):F8-13.

29. Bloom BT, Kattwinkel J, Hall RT, Delmore PM, Egan EA, Trout JR, et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics. 1997;100(1):31-8.

30. Baroutis G, Kaleyias J, Liarou T, Papathoma E, Hatzistamatiou Z, Costalos C. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr. 2003;162(7-8):476-80.

31. Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA. 2005;293(4):470-6.

32. Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med. 1996;334(22):1417-21.

33. Spragg RG, Lewis JF, Walmrath HD, Johannigman J, Bellingan G, Laterre PF, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med. 2004;351(9):884-92.

34. Walmrath D, Gunther A, Ghofrani HA, Schermuly R, Schneider T, Grimminger F, et al. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med. 1996;154(1):57-62.

35. Walmrath D, Grimminger F, Pappert D, Knothe C, Obertacke U, Benzing A, et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J. 2002;19(5):805-10.

36. Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1997;155(4):1309-15.

37. Serrano AG, Ryan M, Weaver TE, Perez-Gil J. Critical structure-function determinants within the N-terminal region of pulmonary surfactant protein SP-B. Biophys J. 2006; 90(1):238-49.

38. Lukovic D, Plasencia I, Taberner FJ, Salgado J, Calvete JJ, Perez-Gil J, et al. Production and characterisation of recombinant forms of human pulmonary surfactant protein C (SP-C): Structure and surface activity. Biochim Biophys Acta. 2006;1758(4):509-18.

39. Wu H, Kuzmenko A, Wan S, Schaffer L, Weiss A, Fisher JH, et al. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest. 2003;111(10):1589-602.

40. Kingma PS, Whitsett JA. In defense of the lung: surfactant protein A and surfactant protein D. Curr Opin Pharmacol. 2006;6(3): 277-83.

41. Sano H, Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol Immunol. 2005;42(3):279-87.

42. Awasthi S. Surfactant protein (SP)-A and SP-D as antimicrobial and immunotherapeutic agents. Recent Pat Antiinfect Drug Discov. 2010;5(2):115-23.

43. William Taeusch H, Lu KW, Goerke J, Clements JA. Nonionic polymers reverse inactivation of surfactant by meconium and other substances. Am J Respir Crit Care Med. 1999;159(5 Pt 1):1391-5.

44. Kobayashi T, Ohta K, Tashiro K, Nishizuka K, Chen WM, Ohmura S, et al. Dextran restores albumin-inhibited surface activity of pulmonary surfactant extract. J Appl Physiol. 1999;86(6):1778-84.

45. Calkovska A, Mokra D, Drgova A, Zila I, Javorka K. Bronchoalveolar lavage with pulmonary surfactant/dextran mixture improves meconium clearance and lung functions in experimental meconium aspiration syndrome. Eur J Pediatr. 2008;167(8):851-7.

46. Lu KW, Goerke J, Clements JA, Taeusch HW. Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium injury. Pediatr Res. 2005;58(2):206-10.

47. Lu KW, Robertson B, Taeusch HW. Dextran or polyethylene glycol added to curosurf for treatment of meconium lung injury in rats. Biol Neonate. 2005;88(1):46-53.

48. Calkovska A, Some M, Linderholm B, Curstedt T, Robertson B. Therapeutic effects of exogenous surfactant enriched with dextran in newborn rabbits with respiratory failure induced by airway instillation of albumin. Pulm Pharmacol Ther. 2008;21(2):393-400.

49. Haitsma JJ, Lachmann U, Lachmann B. Exogenous surfactant as a drug delivery agent. Adv Drug Deliv Rev. 2001;47(2-3):197-207.

50. Blanco O, Lugones Y, Gil DF, Faure R, González Y. Human neutrophil elastase and lung surfactant in acute respiratory distress syndrome. Biotecnol Apl. 2009;26(4):287-92.

51. Cochrane CG, inventor; The Scripps Research Institute, asignee. Compositions for treatment and prevention of pulmonary conditions. United States patent US 7863241 B2. 2011 Jan 4.

52. Arbibe L, Koumanov K, Vial D, Rougeot C, Faure G, Havet N, et al. Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction. J Clin Invest. 1998;102(6):1152-60.

53. Mihelich ED, Schevitz RW. Structure-based design of a new class of anti-inflammatory drugs: secretory phospholipase A(2) inhibitors, SPI. Biochim Biophys Acta. 1999;1441(2-3):223-8.

54. Abraham E, Naum C, Bandi V, Gervich D, Lowry SF, Wunderink R, et al. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Crit Care Med. 2003;31(3):718-28.

55. Turcotte JG, Lin WH, Motola NC, Pivarnik PE, Bhongle NN, Heyman HR, et al. Chemical synthesis and surface activity of lung surfactant phospholipid analogs. III. Chiral N-substituted ether-amide phosphonolipids. Chem Phys Lipids. 1991;58(1-2):81-95.

56. Walther FJ, Waring AJ, Hernandez-Juviel JM, Gordon LM, Schwan AL, Jung CL, et al. Dynamic surface activity of a fully synthetic phospholipase-resistant lipid/peptide lung surfactant. PLoS One. 2007;2(10):e1039.

57. Waring AJ, Walther FJ, Gordon LM, Hernandez-Juviel JM, Hong T, Sherman MA, et al. The role of charged amphipathic helices in the structure and function of surfactant protein B. J Pept Res. 2005;66(6):364-74.

58. Stichtenoth G, Linderholm B, Bjorkman MH, Walter G, Curstedt T, Herting E. Prophylactic intratracheal polymyxin B/surfactant prevents bacterial growth in neonatal Escherichia coli pneumonia of rabbits. Pediatr Res. 2010;67(4):369-74.

59. Stichtenoth G, Jung P, Walter G, Johansson J, Robertson B, Curstedt T, et al. Polymyxin B/pulmonary surfactant mixtures have increased resistance to inactivation by meconium and reduce growth of gram-negative bacteria in vitro. Pediatr Res. 2006;59(3):407-11.

60. Acosta EJ, Policova Z, Lee S, Dang A, Hair ML, Neumann AW. Restoring the activity of serum-inhibited bovine lung extract surfactant (BLES) using cationic additives. Biochim Biophys Acta. 2010;1798(3):489-97.